Before visiting, please review our current visitor policies and COVID-19 information.
Testing The Addition Of An Antibody To Standard Chemoradiation Followed By The Antibody For One Year To Standard Chemoradiation Followed By One Year Of The Antibody In Patients With Unresectable Stage III Non-Small Cell Lung Cancer
To see if we can extend your life and/or prevent your tumor from coming back by adding a study drug durvalumab during chemotherapy and radiation therapy.
DiagnosisLocally advanced non-small cell lung cancer that cannot be removed.
Newly diagnosed stage III NSCLC unresectable, plan for chemo and RT
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1 (Arm A, Arm C): Patients will get the study drug, durvalumab (Arm A). Then will receive durvalumab once every 4 weeks for 1 year (Arm C).
- Group 2 (Arm B, Arm C): Patients will receive only standard chemo/radiation (Arm B). Then will receive durvalumab once every 4 weeks for 1 year (Arm C).
For more information, visit ClinicalTrials.gov
Key Participation Requirements
Male or Female
19 years and older
Methodist Health System Trial Code